WallStreetZenWallStreetZen

NASDAQ: MYGN
Myriad Genetics Inc Stock

$19.96-0.82 (-3.95%)
Updated Feb 3, 2023
MYGN Price
$19.96
Fair Value Price
$21.33
Market Cap
$1.62B
52 Week Low
$13.92
52 Week High
$28.18
P/E
-20.58x
P/B
1.76x
P/S
2.33x
PEG
N/A
Dividend Yield
N/A
Revenue
$661.40M
Earnings
-$77.30M
Gross Margin
70.7%
Operating Margin
-19.53%
Profit Margin
-11.7%
Debt to Equity
0.32
Operating Cash Flow
-$109M
Beta
1.29
Next Earnings
Feb 23, 2023
Ex-Dividend
N/A
Next Dividend
N/A

MYGN Overview

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Zen Score

Industry Average (30)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MYGN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

MYGN ($19.96) is undervalued by 6.43% relative to our estimate of its Fair Value price of $21.33 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
MYGN ($19.96) is not significantly undervalued (6.43%) relative to our estimate of its Fair Value price of $21.33 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MYGN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MYGN due diligence checks available for Premium users.

Be the first to know about important MYGN news, forecast changes, insider trades & much more!

MYGN News

Valuation

MYGN fair value

Fair Value of MYGN stock based on Discounted Cash Flow (DCF)
Price
$19.96
Fair Value
$21.33
Undervalued by
6.43%
MYGN ($19.96) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MYGN ($19.96) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MYGN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

MYGN price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-20.58x
Industry
37.84x
Market
15.09x

MYGN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.76x
Industry
4.54x
MYGN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

MYGN's financial health

Profit margin

Revenue
$156.4M
Net Income
-$35.1M
Profit Margin
-22.4%
MYGN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
MYGN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$1.2B
Liabilities
$295.4M
Debt to equity
0.32
MYGN's short-term assets ($352.30M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MYGN's short-term assets ($352.30M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MYGN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MYGN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$1.8M
Investing
$11.4M
Financing
-$3.6M
MYGN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

MYGN vs Diagnostic & Research Stocks

TickerMarket Cap1d %P/EP/B
MYGN$1.62B-3.95%-20.58x1.76x
NEO$1.59B-1.10%-9.44x1.56x
TWST$1.43B-18.09%-6.26x1.81x
RDNT$1.24B-0.51%179.58x3.95x
ME$1.23B-2.18%-3.74x1.50x

Myriad Genetics Stock FAQ

What is Myriad Genetics's quote symbol?

NASDAQ: MYGN) Myriad Genetics trades on the NASDAQ under the ticker symbol MYGN. Myriad Genetics stock quotes can also be displayed as NASDAQ: MYGN.

If you're new to stock investing, here's how to buy Myriad Genetics stock.

What is the 52 week high and low for Myriad Genetics (NASDAQ: MYGN)?

(NASDAQ: MYGN) Myriad Genetics's 52-week high was $28.18, and its 52-week low was $13.92. It is currently -29.17% from its 52-week high and 43.39% from its 52-week low.

How much is Myriad Genetics stock worth today?

(NASDAQ: MYGN) Myriad Genetics currently has 81,033,816 outstanding shares. With Myriad Genetics stock trading at $19.96 per share, the total value of Myriad Genetics stock (market capitalization) is $1.62B.

Myriad Genetics stock was originally listed at a price of $6.06 in Dec 31, 1997. If you had invested in Myriad Genetics stock at $6.06, your return over the last 25 years would have been 229.21%, for an annualized return of 4.88% (not including any dividends or dividend reinvestments).

How much is Myriad Genetics's stock price per share?

(NASDAQ: MYGN) Myriad Genetics stock price per share is $19.96 today (as of Feb 3, 2023).

What is Myriad Genetics's Market Cap?

(NASDAQ: MYGN) Myriad Genetics's market cap is $1.62B, as of Feb 6, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Myriad Genetics's market cap is calculated by multiplying MYGN's current stock price of $19.96 by MYGN's total outstanding shares of 81,033,816.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.